SynthesisThe international journal of neuropsychopharmacology2015
Cholinesterase Inhibitors for Lewy Body Disorders: A Meta-Analysis.
Synthesis in The international journal of neuropsychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Donepezil for dementia with Lewy bodies: meta-analysis of multicentre, randomised, double-blind, placebo-controlled phase II, III, and, IV studies.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society · 2024Pooled it
- Phase 2A Learnings Incorporated into RewinD-LB, a Phase 2B Clinical Trial of Neflamapimod in Dementia with Lewy Bodies.The journal of prevention of Alzheimer's disease · 2024Trial
- Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration.Nature communications · 2022Trial
- A spatial covarianceJournal of neurology · 2025Article
- Pharmacy Dispensing Records to Describe and Evaluate the Use of Acetylcholinesterase Inhibitors Among Swedish Antipsychotic Drug Users with Symptoms of Lewy Body Dementia.Drugs - real world outcomes · 2025Article
- Cognition and Activity of Daily Living Function in people with Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Differential diagnosis of MCI with Lewy bodies and MCI due to Alzheimer's disease by visual assessment of occipital hypoperfusion on SPECT images.Japanese journal of radiology · 2024Article
- Technology-based group exercise interventions for people living with dementia or mild cognitive impairment: A scoping review.PloS one · 2024Article
- Factors Associated With Increased Health Care Utilization for Patients With Dementia With Lewy Bodies: A Narrative Review.Journal of patient-centered research and reviews · 2024Review
- Paradigm Shift: Multiple Potential Pathways to Neurodegenerative Dementia.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023Article
- Association between antidementia medication use and mortality in people diagnosed with dementia with Lewy bodies in the UK: A retrospective cohort study.PLoS medicine · 2022Article
- Acetyl-cholinesterase-inhibitors slow cognitive decline and decrease overall mortality in older patients with dementia.Scientific reports · 2022Article
- Cholinesterase inhibitors for the treatment of dementia: real-life data in Hungary.GeroScience · 2022Article
- CCCDTD5 recommendations on the deprescribing of cognitive enhancers in dementia.Alzheimer's & dementia (New York, N. Y.) · 2022Article
- Agitation and Dementia: Prevention and Treatment Strategies in Acute and Chronic Conditions.Frontiers in neurology · 2021Review
- Immunotherapies for Aging-Related Neurodegenerative Diseases-Emerging Perspectives and New Targets.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Review
- Cholinergic muscarinic MBrain communications · 2020Article
- Alzheimer's disease medication and outcomes of hospitalisation among patients with dementia.Epidemiology and psychiatric sciences · 2019Article
- Clinical drug development for dementia with Lewy bodies: past and present.Expert opinion on investigational drugs · 2019Review
- A comparison of machine learning classifiers for dementia with Lewy bodies using miRNA expression data.BMC medical genomics · 2019Article
Corrections and comments
- Erratum issuedErratum.2016
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe performed a meta-analysis of cholinesterase inhibitors for patients with Lewy body disorders, such as Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies.
methodsThe meta-analysis included only randomized controlled trials of cholinesterase inhibitors for Lewy body disorders.
resultsSeventeen studies (n = 1798) were assessed. Cholinesterase inhibitors significantly improved cognitive function (standardized mean difference [SMD] = -0.53], behavioral disturbances (SMD = -0.28), activities of daily living (SMD = -0.28), and global function (SMD = -0.52) compared with control treatments. Changes in motor function were not significantly different from control treatments. Furthermore, the cholinesterase inhibitor group had a higher all-cause discontinuation (risk ratio [RR] = 1.48, number needed to harm [NNH] = 14), discontinuation due to adverse events (RR = 1.59, NNH = 20), at least one adverse event (RR = 1.13, NNH = 11), nausea (RR = 2.50, NNH = 13), and tremor (RR = 2.30, NNH = 20).
conclusionsCholinesterase inhibitors appear beneficial for the treatment of Lewy body disorders without detrimental effects on motor function. However, a careful monitoring of treatment compliance and side effects is required.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.